A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts mortality. The effect of different ART regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind, trial of maraviroc versus efavirenz, in combination with zidovudine-lamivudine, in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by greater CD8+ T-cell decline.
http://ift.tt/2yVcjna
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.